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Abstract
Natural killer T (NKT) cell is a distinct population of T lymphocytes that can rapidly release massive amount of Th1
and Th2 cytokines upon the engagement of their T cell receptor with glycolipids presented by CD1d. The secreted
cytokines can promote cell-mediated immunity to kill tumor cells and intracellular pathogens, or suppress autoreactive
immune cells in autoimmune diseases. Thus, NKT cell is an attractive target for developing new therapeutics
to manipulate immune system. The best-known glycolipid to activate NKT cells is α-galactosylceramide (α-GalCer), which
has been used as a prototype for designing new NKT stimulatory glycolipids. Many analogues have been generated by
modification of the galactosyl moiety, the acyl chain or the phytosphingosine chain of α-GalCer. Some of the analogues
showed greater abilities than α-GalCer in polarizing immune responses toward Th1 or Th2 dominance. Among
them, several analogues containing phenyl groups in the lipid tails were more potent in inducing Th1-skewed
cytokines and exhibited greater anticancer efficacy than α-GalCer. Analyses of the correlation between structure and
activity of various α-GalCer analogues on the activation of iNKT cell revealed that CD1d–glycolipid complexes
interacted with the same population of iNKT cell expressing similar T-cell receptor Vβ as α-GalCer. On the other hand,
those phenyl glycolipids with propensity for Th1 dominant responses showed greater binding avidity and stability than
α-GalCer for iNKT T-cell receptor when complexed with CD1d. Thus, it is the avidity and stability of the ternary
complexes of CD1d-glycolipid-iNKT TCR that dictate the polarity and potency of immune responses. These
findings provide a key to the rationale design of immune modulating glycolipids with desirable Th1/Th2 polarity for
clinical application. In addition, elucidation of α-GalCer-induced anergy, liver damage and accumulation of myeloid
derived suppressor cells has offered explanation for its lacklustre anti-cancer activities in clinical trials. On other hand,
the lack of such drawbacks in glycolipid analogues containing phenyl groups in the lipid tails of α-GalCer coupled with
the greater binding avidity and stability of CD1d-glycolipid complex for iNKT T-cell receptor, account for their superior
anti-cancer efficacy in tumor bearing mice. Further clinical development of these phenyl glycolipids is warranted.
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Background
Natural killer T (NKT) cells play a central role in con-
necting innate immunity and adaptive immunity. They
can modulate immune responses by orchestrating other
immune cells, including T cells, B cells, natural killer
(NK) cells and dendritic cells (DCs) [1]. There are two
major subpopulations of NKT cells, classical (or type I)
NKT cells and non-classical (or type II) NKT cells [2–4].
Those two subpopulations of NKT cells are response to
lipid antigens in a CD1d-dependent manner. Many glyco-
lipid antigens for NKT cells have been identified, including
bacterial glycolipids such as α-galacturonosyl ceramide, α-
glucuronosyl ceramide and α-galactosyl diacylglycerol and
mammalian glycolipids such as isoglobotrihexosylceramide
(iGb3) and disialoganglioside GD3 [5–7]. In addition, α-
galactosylceramide (α-GalCer) isolated from marine sponge
is found to have a potent activity to activate the classical
NKT cells and display anticancer effects in tumor-bearing
mouse model. The robust immune stimulating activities of
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α-GalCer inspire researchers to use the α-GalCer as
template to design more potent immune modulating
glycolipids. For example, glycolipid OCH prevents the
experimental autoimmune encephalomyelitis [8], α-C-
Gal protects mice against malaria and melanoma
metastases [9] and phenyl-glycolipids suppress tumor
growth in mouse models as well as strong adjuvant
effect on DNA vaccine [10, 11]. The differential bio-
logical activities of various α-GalCer analogues provide
valuable insights into the relationship between structural
modification of α-GalCer and the immune-modulating
activities and thereby facilitating the design of novel
analogues with desirable properties for various clinical
applications.
Subsets and functions of NKT cells
NKT cells are a unique subset of T lymphocytes that
coexpress α/β T cell receptor (TCR) and NK lineage
markers, i.e. NK1.1, CD122 (IL-2Rβ) and various Ly49
molecules. Based on the phenotype and content of cyto-
kines, NKT cells have been divided into two main sub-
sets: type I NKT cells, known as invariant NKT (iNKT)
cells producing IFN-γ, IL-2, IL-4, IL-5 and IL-13, and
type II NKT cells which encompass many diverse NKT
cells secreting IFN-γ, TNF-α, IL-17A and IL-6 [12]. The
iNKT cells can be found in thymus, liver, bone marrow,
spleen and peripheral blood. In mice, iNKT cells comprise
of approximately 1 to 3% of lymphocytes in the circulation
and are enriched in the liver where iNKT can constitute
up to 30% of resident lymphocytes. These cells are CD1d-
restricted CD4+ or CD4−CD8− T cells with NK markers
and exhibit an activated phenotype (CD44highLy6Chigh IL-
2Rβhigh). The TCR usage of iNKT cells is quite unique
with a semi-invariant α-chain consisting of Vα14Jα18, and
preferential usages of Vβ2, Vβ7 or Vβ8.2 for β-chain in
mice [13–18]. In human, a similar population of cells ex-
pressing Vα24Jα18 and Vβ11 has been identified [19, 20].
Although the type II NKT cells are also responsive to
CD1d-presented glycolipids, which do not include α-
GalCer [21], they express polyclonal TCR repertoires simi-
lar to the highly diverse TCRs of conventional CD4 and
CD8 T cells.
Unlike conventional T cells, which recognize peptides
presented by major histocompatibility complex (MHC)
molecules, both iNKT or type II NKTcells recognize glyco-
lipid antigens presented by CD1d proteins which are non-
polymorphic MHC class I–like molecules [22–24]. CD1d
proteins are expressed on cells of hematopoietic origin such
as dendritic cells, B cells, T cells and macrophages [25]. Ac-
cording to the crystal structure of CD1d protein, antigen-
binding site of CD1d molecules is composed of two chan-
nels, A’ and F’ channels, which bind to an acyl chain and a
phytosphingosine chain, respectively [26–31]. Antigens
such as glycosylceramide and glycosylphosphatidylinositol
could be presented by CD1d. Their alkyl chains are inserted
into hydrophobic grooves A’ and F’ channels of CD1d so
that their carbohydrate moieties protrude to contact with
TCR of NKTcells [23, 32].
Upon engagement with CD1d/α-GalCer complex, iNKT
cells become activated with rapid production of cytokines
within minutes [33], such as interleukin-4 (IL-4) and
interferon-γ (IFN-γ), along with upregulation of activation
markers such as CD69, augmented cell proliferation and
increased cytotoxic capacity [23, 34–36]. The secreted
cytokines will not only trigger activation of T cells, NK
cells, B cells and dendritic cells but also direct immune
responses toward Th1 or Th2 responses [37, 38]. For
instance, IFN-γ promotes Th1 cell differentiation and NK
cell activation, which is essential for defense against
tumors and various intracellular pathogens. Conversely,
IL-4 controls the initiation of Th2 responses, which inhibit
Th1-mediated autoimmune responses such as collagen-
induced arthritis (CIA), experimental autoimmune en-
cephalomyelitis (EAE) and type I diabetes in NOD mice.
Hence, iNKT cells are thought to play a central role in
innate and adaptive immunity against viruses, bacteria,
parasites, autoimmune diseases and cancer [23, 39–42].
Type II NKT cells do not respond to α-GalCer and
therefore they cannot be identified by α-GalCer/CD1d
tetramers. Such technical limitations have hindered efforts
to interrogate type II NKT cells and, consequently, rela-
tively little is known about their roles in immune system.
So far, a major subset of type II NKT cells has been found
to respond to β-linked self-glycolipid sulfatide [43]. Com-
paring the crystal structures of type I NKT-α-GalCer/
CD1d complex and type II NKT cell TCR-sulfatide/CD1d
complex, Girardi et al. found that the type II NKT TCR
bound to sulfatide/CD1d with an perpendicular orienta-
tion but the type I NKT TCR bound to α-GalCer/CD1d
with an diagonal orientation [44]. This study suggests that
the immune-modulating effects of iNKT and type II NKT
cells might be quite different. Indeed, it is known that type
II NKT cells played an important role in anergy induction
in the inflammatory liver [45], suppression of graft-versus-
host disease (GVHD) [46] and inhibition of airway asthma
induced by Type I NKT cells in mouse model [47]. In
addition, type II NKT cells might be involved in cancer
progression by secreting IL-13 to inhibit tumor-specific
CD8+ T cells [48]. In human, an increase in IL-13-
secreting type II NKT cells stimulated by lysophosphoti-
dylcholine was observed in patients with multiple mye-
loma [49]. Moreover, tumor growth was significantly
increased in Jα18−/− mice, which lack type I NKT cells but
still retain type II NKT cells, compared to that in CD1d−/−
mice, which lack both type I and type II NKT cells [50].
Similarly, Izhak et al. demonstrated that enhanced tumor
growth in Jα18-/- mice was not undermined by blocking
regulatory T (Treg) cell blockade with anti-CD25 antibody
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alone, but was abrogated when both type II NKT cells and
Tregs were blocked. Importantly, adoptive transfer of type
I NKT cells can restore the protection against tumor in
Jα18−/− mice treated with anti-CD25 antibody [51]. These
results indicate that type II NKT cells might suppress
tumor immunity to promote tumor progression, and type
I NKT cells might inhibit the immune suppressive ability
of type II NKT cells.
Avidity and stability of TCR-glycolipids-CD1d
complex dictate the differential capacities of
α-GalCer and its analogues for NKT activation
α-GalCer, also known as KRN7000, is a simplified glycolipid
analogue of agelasphin, which was originally isolated from a
marine sponge Agelas mauritianus [52, 53]. α-GalCer is
composed of an α-linked galactose, a phytosphingosine and
an acyl chain. Preclinical evidence of the antitumor activity
of α-GalCer has spurred research toward the identification
of its mechanism of action [23, 54]. It is a well characterized
antigen for CD1d-reactive iNKT cells in mouse and human
[55–57]. X-ray crystallographic analysis of binary complex
of α-GalCer and CD1d molecule revealed that the long
lipid chain of α-GalCer is stabilized by hydrophobic interac-
tions with amino acids from the β-sheet floor and helices of
CD1d. Specifically, the A’ and the F’ channels of CD1d can
accommodate an alkyl chain up to 26 and 18 carbon atoms
long, respectively [26]. Furthermore, the length of lipids of
α-GalCer can modulate the affinity of iNKT cell TCR and
the threshold of iNKT cell activation [58]. OCH, an α-
GalCer analogue with a shorter phytosphingosine chain,
stimulates iNKT cells to secrete higher amounts of IL-4
than IFN-γ, triggering the immune response toward Th2
(Fig. 1). The possible molecular mechanisms of OCH-
induced Th2 response might be related to its less avidity
and stability in binding to CD1d than α-GalCer, leading to
a less sustained TCR stimulation on iNKT cells [8, 59, 60].
Other α-GalCer analogues containing sulfonamide linkage
to acyl chain induced Th2 response comparable to OCH in
mouse splenocytes [61]. Besides, our group has shown that
α-GalCer analogues containing a phenyl group in their acyl
tail are more effective than α-GalCer in inducing Th1 cyto-
kines/chemokines and human NKT cell expansion. Similar
to α-GalCer, phenyl glycolipids cannot induce cytokine pro-
duction in CD1d knockout mouse, suggesting that presen-
tation of phenyl glycolipids by CD1d protein is necessary to
activate iNKT cells [60]. Moreover, one of the phenyl glyco-
lipids, 7DW8-5 which has a shorter fatty acyl chain with a
fluorinated benzene ring at the end, displayed adjuvant ac-
tivity for malaria vaccine and enhanced CD8+ T cell re-
sponse in non-human primate [62]. The differential
cytokine response induced by phenyl glycolipids did not re-
sult from differential usage of TCR β chain. In fact, the
Fig. 1 Activation of NKT cells by α-galactosylceramide and its analogs. CD1d molecule on the antigen presenting cells (APCs) presents α-galactosylceramide
and various analogs, such as phenyl α-GalCer (C34) and OCH, to the Vα14 T cell receptor (TCR) of iNKT cells, and triggers the activation of iNKT
cells to secrete cytokines, e.g. interferon-γ (IFN-γ) and interleukin-4 (IL-4). Modification of the α-GalCer at its acyl chain or phytosphingosine
chain can manipulate the iNKT cells to produce different amount of IL-4 or IFN-γ to polarize immune response toward Th1 or Th2
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major β chain used by iNKT cells for the recognition of
phenyl glycolipids and α-GalCer were Vβ8.1 and Vβ8.2 in
mouse and Vβ11 in human. On the other hand, phenyl gly-
colipids displayed greater binding strengths between CD1d-
glycolipid complex and iNKT cells than α-GalCer. Add-
itionally, the rate of dissociation of CD1d-phenyl glycolipid
complex from iNKT TCR was significantly slower than that
of CD1d-α-GalCer complex. These results suggest that
both the avidity and stability of the ternary complex of
CD1d-glycolipid-iNKT TCR play a key role in dictating the
induction of cytokines/chemokines. Notably, the binding
strength of the ternary structure CD1d-glycolipid-iNKT
TCR is much more relevant to iNKT cell activation than
that of the binary structure CD1d-glycolipid, as reflected
by the differential cytokine responses to glycolipids
with identical lipid tails but different glycan head [63].
More importantly, unlike α-GalCer, these phenyl glyco-
lipids do not induce NKT cell anergy nor accumulation
of myeloid-derived suppressor cells (MDSCs) [10, 11,
64], which will be elaborated in later section.
In addition, the orientation and position of hydroxyl
group at the galactose ring of α-GalCer are believed to
be crucial for iNKT cell recognition [6]. The 2′, 3′, and
4′-OH of the galactose moiety form hydrogen bonds
with Gly96a, Phe29a and Ser30a, respectively, of the
invariant TCR α-chain. Upon removal of the 2′-OH, the
cytokine response declined. However, the 3′- or 4′-de-
oxy or -fluoro analogues of α-GalCer remain active [65].
According to the crystal structure of ternary complex of
NKT TCR/α-GalCer/CD1d, the 6′-OH of the galactose
moiety of α-GalCer points toward solvent [6], and thus
it might or might not influence the binding of iNKT
TCR to α-GalCer/CD1d complex. Indeed, addition of an
extra Gal [66] or small fluorophores [67] at 6′-OH of
the galactose moiety retains the activity to stimulate
NKT cells. Conjugation with polyethylene glycol at 6′-
amide group of the galactose moiety activates murine
iNKT cells more efficiently than α-GalCer. When acting
as an adjuvant for the β-galactosidase protein vaccine,
the α-GalCer analogue with pegylation, which increased
the water solubility, at the 6′-amide of galactose moiety
elicited high titers of antigen-specific antibodies in
mouse, even though it induced lower production of IFN-
γ than α-GalCer [68]. In contrast, α-GalCer analogue
with a naphthylurea at 6′-amide of galactose moiety in-
duced Th1 bias immune response and prevented lung me-
tastasis of melanoma [69] whereas α-GalCer analogue
with a methyl group at 6′-OH of galactose moiety induced
slightly higher production of IL-4 and IFN-γ in mouse
[70]. We also showed that Gal-6′- phenylacetamide-
substituted α-GalCer analogues carrying p-nitro-, p-
tert-butyl, or o-, m-, or p-methyl groups elicited
higher IFN-γ/IL-4 secretion ratios than α-GalCer [71].
In contrast, we have recently shown that adding acyl
chain at the 6′-OH of galactose moiety of α-GalCer
can stimulate iNKT cells to secrete more Th2-biased
cytokines [72]. Interestingly, two 6′-OH analogues of α-
GalCer, NU-α-GalCer and PyrC-α-GalCer, induced strong
Th1-biased immune response leading to reduced lung me-
tastasis in the B16 melanoma model [73]. These findings
suggest that modifications at 6′-OH of galactose moiety
may change the interaction between NKT TCR and α-
GalCer-CD1d complex, thereby modulating the cytokine
secretion of iNKT cells in vitro and in vivo.
Based on the X-ray crystallography study, the NH
group of the amide of α-GalCer phytosphingosine
chain forms hydrogen bond to Thr156 at the α2
loop of mouse CD1d [29], indicating that the NH
group might play a role in the activity of α-GalCer.
Indeed, the NH group isomer, having the inverted
NH stereochemistry, showed weaker activity for
stimulating proliferation of mouse iNKT cells and no
activity for human iNKT cells [74]. RCAI-18, α-
GalCer analogue with azetidine ring, induced slightly
lower levels of IFN-γ, IL-2, IL-4, IL-10 and IL-13
when compared with α-GalCer. However, RCAI-8, a
RCAI-18 analogue with replacement of the azetidine
ring with pyrrolidine ring, did not stimulate murine
iNKT cells to produce cytokines [75]. Furthermore,
Shiozaki et al. showed that replacing the amide
group of α-GalCer with an ester reduced the secre-
tion of IFN-γ and IL-4 [76]. In our study, we found
that substituting the hydrogen of amide group of α-
GalCer with methyl group lowered its capacity in
inducing cytokine production of iNKT cell [72]. Be-
sides, α-GalCer analogue DB06-1, which contains the
substitution of a carbonyl oxygen with a sulfur atom,
can increase IFN-γ and IL-2p70 production and acti-
vate NK cells in vivo [77]. In addition, α-C-GalCer, a
C-glycoside of α-GalCer, displayed a more potent anti-
malarial activity and antitumor activity in mice [9],
but it did not effectively stimulate human iNKT cells
in vitro [78]. Those data suggest that different modifi-
cations of phytosphingosine or acyl chain may affect
the binding affinity of TCR with glycolipids-CD1d
complex, and thereby modulating the magnitude and
the Th1/Th2 polarity of responses of iNKT cells.
Clinical trials of α-galactosylceramide
In preclinical studies, the anti-cancer activity of α-
GalCer has been demonstrated in tumor-bearing mouse
models. Prompted by these findings, Giaccone et al.
conducted a phase I clinical trial of α-GalCer in
patients (n = 24) with advance cancer. The dose was
escalated from 50 to 4800 μg/m2 at a schedule of
intravenous injection on days 1, 8 and 15 of a 4-
weekly cycle. Toxicities of α-GalCer were minimal, in-
cluding vomiting, malaise and chills in one patient and
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grade 3 fever and headache in another patient. All side
effects occurred after the first administration only.
Neither drug accumulation nor serum saturation of α-
GalCer was observed by pharmacokinetic analyses.
Furthermore, no detectable trace of α-GalCer was
found in the urine at any dose level. Surprisingly, in
patients with high number of NKT cells (>333 cells/
mL), the number of circulating iNKT cells rapidly
declined to undetectable levels within 24 h after the
first injection of α-GalCer. Even after two additional
injections, circulating iNKT cells remained negligible
or undetectable. Notably, patients with pretreatment
iNKT cell numbers higher than median number in all
patients had greater cytokine productions induced by
α-GalCer. Five of 10 patients in NKT-high group
showed significant increases in serum levels of both
GM-CSF and TNF-α. In contrast, GM-CSF and TNF-α
levels barely rose in the NKT-low group after α-
GalCer administration [79]. In addition, the impacts of
age and cancer status were assessed to provide
information for iNKT cell-based immunotherapy [80].
The percentages of circulating iNKT cell were signifi-
cantly lower in patients with melanoma (n = 17) and
breast cancer (n = 10) than in healthy donors (n = 40).
The percentages of circulating iNKT cells were also
lower in patients with colorectal cancer (n = 33), lung
cancer (n = 8) and RCC (n = 10) than healthy controls
but the difference did not reach statistical significance.
In addition, in vitro expansion capability of iNKT cells
from cancer patient in response to α-GalCer was less
than that from healthy donor. Moreover, the percent-
age and absolute number of circulating iNKT cells
decreased with increasing age, although age did not
affect the expansion capability of iNKT cells stimu-
lated with α-GalCer [80]. These results suggest that
the cytokine production and iNKT cell expansion in-
duced by α-GalCer in patients depend on the pre-
treatment circulating iNKT cell population size which
is influenced by type of cancer and patient age.
Several studies have shown that α-GalCer-pulsed
DC can inhibit tumor growth in mouse and expand
human iNKT cells in vitro [81–83]. These findings
prompted a few clinical trials to evaluate the antitu-
mor efficacy of α-GalCer-pulsed DC. In the phase I
trial conducted by Nieda et al., patients (n = 12) re-
ceived 5 × 106 α-GalCer-pulsed DC on day 0 and 14.
Increased serum level of IFN-γ and number of NKT
cells were observed initially but the number of NKT
cells fell by day 2 after treatment. The majority of
patients experienced temporary exacerbation of tumor
symptoms, including enlargement of tumor, bone pain
and biochemical abnormalities. However, a few pa-
tients showed tumor responses, such as decreased
serum tumor markers (n = 2), increased necrosis in
tumor (n = 1) and improvements in hepatocellular
enzyme levels (n = 2) [84]. Chang et al. demonstrated
that injection of unpulsed DC at week 0 and α-
GalCer-pulsed matured DC at week 4 and 8 led to a
dramatic expansion of NKT cells in all patients (n =
5) after the third injection [85]. In addition, Uchida
et al. administered α-GalCer-pulsed DC into the
nasal submucosa of patients (n = 9) and found that
the number of circulating NKT cells increased [86].
Kunii et al. treated 8 patients with recurrent head
and neck squamous cell carcinoma by intra-arterial
infusion of ex vivo expanded autologous iNKT cells
in combination with nasal submucosal injection of α-
GalCer-pulsed DC. They found that both the number
of circulating iNKT cells and IFN-γ-producing cells
increased (7/8), However, mild to severe adverse
events were observed i.e. a grade 3 pharyngocuta-
neous fistula (n = 1), low-grade fever (n = 4), headache
(n = 1), and fatigue (n = 2). In spite of these adverse
events, three partial responses, four stable diseases
and one progressive disease were observed [87]. Fur-
thermore, the administration routes of α-GalCer-
pulsed DC were evaluated in patients with metastatic
malignancy [88]. Increases in serum IFN-γ levels in
patients were seen after intravenously injection of 5
× 106 of α-GalCer-pulsed DC but were not observed
in patients after intradermally injection of the same
dose of α-GalCer-pulsed DC. Notably, six patients
had stable disease, which was defined as no substantial in-
crease in tumor masses or tumor markers, during the
study period of 3 months. Taken together, these reports
suggest that α-GalCer-pulsed DC might induce clinically
beneficial immune responses in patients with cancer.
Moreover, the antiviral effects of α-GalCer on hepatitis
viruses were evaluated. A randomized placebo-controlled
phased I/II trial of α-GalCer in chronic hepatitis C virus
(HCV) infection was conducted by Veldt et al. A total of
40 patients were enrolled and three dosage levels of α-
GalCer (0.1, 1 and 10 μg/kg) were tested. α-GalCer was
well tolerated in patients with HCV, with only mild
adverse events including fatigue, myalgia, back pain, head-
ache, rhinitis, fever, chills and dizziness. As shown in Giac-
cone’s report [79], the number of circulating iNKT
dropped immediately after the first injection of α-GalCer
in patients with HCV, but recovered approximately 2 days
later. Subsequent second and third injection of α-GalCer
did not further enhance the iNKT cell number. In several
individuals, productions of IFN-γ and TNF-α were
observed. One patient showed a mark decrease in HCV
RNA after the first injection of α-GalCer, but no further
reduction after the second and third injection. At the end
of this trial, no significant changes in HCV RNA between
the two groups were noted [89]. Another randomized
placebo-controlled phased I/II trial of α-GalCer in 27
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patients with chronic hepatitis B virus (HBV) was con-
ducted by Woltman et al. [90], using the same dose-
schedule as Veldt’s study [89]. The adverse events were
mostly flu-like syndromes except that four patients,
who received ≥ 1 μg/Kg of α-GalCer, had fever and
severe rigors lasting for 1 h to 2 days. This might result
from relatively high iNKT cell levels in the blood of
HBV patients, which had high stimulatory effects on
the immune system. The number of circulating iNKT
cells fluctuated, similar to the report by Veldt et al. A
transient rise in serum TNF-α was observed only in
patients with high pretreatment iNKT cell number.
Four patients showed decrease in HBV DNA levels fol-
lowing the first injection of α-GalCer, but only one
sustained decrease in HBV DNA levels after the
second and third injection of α-GalCer. In general, the
HBV DNA changes in patients injected with α-GalCer
was not statistically significantly different from those
in placebo group [90].
Overall, the antitumor and antiviral efficacies of α-
GalCer in human are deemed too meagre to warrant
further clinical trials. On the other hand, the route of
injection, dose and schedule might have influenced the
therapeutic efficacy of α-GalCer. Although α-GalCer
did not show robust clinical efficacy in these early
phase clinical trials, the use of more potent Th1-
biased α-GalCer analogues containing phenyl group in
lipid tail might improve the anti-tumor efficacy in
human in the future.
Possible mechanisms for the limited clinical
activities of α-GalCer
The lacklustre clinical efficacy of α-GalCer in cancer
and hepatitis may be attributable to α-GalCer in-
duced liver toxicity [91], NKT cells anergy [92] and
myeloid-derived suppressor cells (MDSCs) accumula-
tion [64]. These features might have undermined the
clinical efficacy of α-GalCer.
One day after injection of α-GalCer in mice, several
white spots (0.5–1 mm in diameter) were readily
discernible on the surface of liver, which consisted of
hepatocyte damage accompanied by lymphocyte infil-
tration in liver parenchyma and a rise in serum levels
of SGOT and SGPT. Such hepatocyte damage induced
by α-GalCer was dependent on NK/NKT cells [91].
Furthermore, we demonstrated that α-GalCer signifi-
cantly upregulated the expression of TRAIL and FasL
in liver iNKT cells, leading to injury of liver cells
which constitutively express Fas and death receptor 5
(DR5) (Fig. 2). In comparison, negligible or only a very
slight increase of the TRAIL and FasL on liver iNKT
cells was detected in mice injected with the α-GalCer
Fig. 2 Mechanisms of α-GalCer induced anergy of iNKT and accumulation of myeloid-derived suppressor cells (MDSCs). The binding of
CD1d-α-GalCer to TCR of iNKT cells triggers iNKT cell anergy via upregulation of egr-2 or egr-3 in NKT cells. The engagement of CD1d-α-GalCer-TCR also
induces expression of FasL on iNKT cells. Binding of FasL to Fas or TRAIL on hepatocytes may cause hepatocyte injury and trigger IL-33 release, which
in turns stimulated G-CSF production by macrophage, leading to increased number of MDSCs
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analogues containing phenyl group at the acyl chain
[64]. Indeed, no white spots on liver were observed in
mice injected with these phenyl analogues, suggesting
that these phenyl glycolipids may have the advantage
of little or no hepatotoxicity in human use.
Another feature of α-GalCer that may limit its
clinical efficacy is that α-GalCer induces iNKT cell
anergy. Upon in vitro re-stimulation with α-GalCer,
splenocytes from α-GalCer-injected mice produced
only low levels of cytokines and decreased prolifera-
tion ability as compared to the first injection. This
unresponsive phenomenon of α-GalCer treated iNKT
cells was thymus independent and can be abrogated
by IL-2 [93]. It is well known that in T cells, stimu-
lation of TCRs with weaker ligands induces anergy
via up-regulation of the transcription factor egr-2/3,
leading to the expression of cbl-b and programmed
cell death protein 1 (PD-1) [94]. In line with T cell
anergy, the α-GalCer-induced anergy of iNKT cells
has been shown to up regulate the expression of cbl-b,
PD1 and egr-2/3. Interestingly, α-GalCer analogues with
phenyl group, which display greater binding avidity and
stability to iNKT TCR than α-GalCer [60], did not induce
the expression of PD-1 and cbl-b, nor anergy upon
repeated treatment [64].
The lack of effective elimination of MDSCs by α-
GalCer is another potential drawback. MDSC is a
population of myeloid cells that co-express CD11b+
and Gr1+ surface markers and has been shown to
suppress anti-CD3/anti-28 induced T cells prolifera-
tion [95], downregulate CD3ζ-chain expression [96],
inhibit the CD8 T cells cytotoxicity, induce T cells
apoptosis [97] and reduce the cytotoxicity of NK cells
and activation of NKT cells [98]. Thus, it contributes
to hyporesponsiveness of various immune effector cells,
resulting in enhanced tumor progression and metastasis
[99, 100]. The suppressive activities of MDSCs are
achieved by regulation of L-arginine metabolic path-
ways. L-arginine is metabolized by arginase to generate
urea and L-ornithine or is converted into citrulline and
nitric oxide (NO) by inducible nitric oxide synthase
(iNOS) [101]. It has been reported that MDSCs pro-
duce NO to suppress the immune response in the
tumor microenvironment [102]. Repeated injection of
α-GalCer maintained high level of MDSCs in the spleen
and enhanced the expression of PD-1 and PD-L1 as
well as arginase 1 and iNOS on MDSCs. Moreover, ac-
cumulation of MDSCs was at least in part attributed to
up-regulation of G-CSF through IL-33, which was trig-
gered by liver damage [64]. Since treatment of Jα18−/−
mice with α-GalCer failed to show accumulation of
MDSCs (Fig. 3), in contrast to wild type mice, accumula-
tion of MDSC induced by α-GalCer is iNKT cell-
dependent. Thus, strategies to diminish the number or
suppressive activity of MDSCs induced by α-GalCer
might enhance the anti-tumor effect of α-GalCer. Re-
cent report that suppression of iNOS by L-NAME,
which is an inhibitor for iNOS, enhanced the anti-
tumor effect of α-GalCer is consistent with this notion
[103]. Another strategy is to modify the structure of α-
GalCer to reduce the MDSC-promoting activity thereby
enhancing its anti-tumor activity. Indeed, phenyl gly-
colipids did not induce MDSC accumulation in the
spleen nor in the tumor microenvironment in contrast
to α-GalCer. Such structural modification of α-GalCer
might represent a step in the right direction for the
development of more potent NKT-stimulatory glyco-
lipids for cancer therapy [64].
Fig. 3 MDSC accumulation induced by α-GalCer is iNKT cell-dependent. BALB/c and Jα18−/− mice (n = 3 per group) were intravenously injected
with α-GalCer (2 μg/mouse) or vehicle (1% DMSO). Three days after administration, MDSCs (CD11b + Gr1+) were determined by FACS analysis. a
Representative dot plots of MDSCs in the presence/absence of α-GalCer in wild type and Jα18−/− mice were shown. b The percentage and total
number of MDSCs in splenocyte from each mouse of indicated group are presented and shown as mean ± SD. ***, p < 0.01 as compared
with vehicle
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Conclusion
Various modifications on α-GalCer have been made, and
studies of these α-GalCer analogues have shed light on
the direction to manipulate the activation of iNKT with
desired immune responses. Some of these α-GalCer ana-
logues have demonstrated improved efficacy as anticancer
agents, vaccine adjuvants and anti-autoimmune agents in
animal studies. Therefore, understanding the correlation
between structure and activity of α-GalCer analogues on
the activation of iNKTcells and their molecular mechanism
related to immune modulation should facilitate the de-
velopment of potent immune modulating glycolipids
for various diseases. Besides, the route of injection,
dose and treatments schedule might influence the thera-
peutic efficacy of α-GalCer. Although the α-GalCer did
not show good clinical responses in the phase I clinical
trials, using low immune suppressive α-GalCer analogues
and optimized treatment schedule might show better anti-
tumor efficacy in human in the future.
Abbreviations
CIA: Collagen-induced arthritis; DCs: Dendritic cells; DR5: Death receptor 5;
EAE: Experimental autoimmune encephalomyelitis; GVHD: Graft-versus-host
disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; IFN-γ: Interferon-γ;
iGB3: isoglobotrihexosylceramide; IL-4: Interleukin-4; iNKT: invariant NKT;
iNOS: inducible nitric oxide synthase; MDSCs: Myeloid-derived suppressor
cells; MHC: Major histocompatibility complex; NK: Natural killer; NKT: Natural
killer T; NO: Nitric oxide; PD-1: Programmed cell death protein 1; TCR: T cell
receptor; Treg: Regulatory T; α-GalCer: α-galactosylceramide
Acknowledgements
We are indebted to Hsiao-Wei Wu for her excellent scientific illustration.
Funding
This research was supported by grants from the Ministry of Health and
Welfare (DOH95-DC-1411), the Ministry of Science and Technology (MOST
105-2320-B-182A-006), the Chang Gung Medical Foundation (OMRPG3C0014
and CMRPG3D1491-3) and Academia Sinica in Taiwan.
Availability of data and materials
Not applicable.
Authors’ contributions
JRH, JTH and ALY have contributed to the organization of the content for
this manuscript. JRH and JTH collected relevant information and prepared
the draft. ALY drafted and revised the manuscript. All authors read and
approved the final manuscript.
Competing interests
ALY and JTH hold the patent on C34. The authors declare that the patent




Ethics approval and consent to participate
Not applicable.
Received: 30 September 2016 Accepted: 20 February 2017
References
1. Cerundolo V, et al. Harnessing invariant NKT cells in vaccination strategies.
Nat Rev Immunol. 2009;9(1):28–38.
2. Godfrey DI, et al. NKT cells: what’s in a name? Nat Rev Immunol. 2004;4(3):231–7.
3. Cardell S, et al. CD1-restricted CD4+ T cells in major histocompatibility
complex class II-deficient mice. J Exp Med. 1995;182(4):993–1004.
4. Behar SM, et al. Diverse TCRs recognize murine CD1. J Immunol.
1999;162(1):161–7.
5. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev
Immunol. 2007;25:297–336.
6. Borg NA, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-
cell receptor. Nature. 2007;448(7149):44–9.
7. Pellicci DG, et al. Differential recognition of CD1d-alpha-galactosyl ceramide
by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors.
Immunity. 2009;31(1):47–59.
8. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents
autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.
Nature. 2001;413(6855):531–4.
9. Schmieg J, et al. Superior protection against malaria and melanoma
metastases by a C-glycoside analogue of the natural killer T cell ligand
alpha-Galactosylceramide. J Exp Med. 2003;198(11):1631–41.
10. Chang YJ, et al. Potent immune-modulating and anticancer effects of NKT cell
stimulatory glycolipids. Proc Natl Acad Sci U S A. 2007;104(25):10299–304.
11. Hung JT, et al. Potent adjuvant effects of novel NKT stimulatory glycolipids
on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antiviral
Res. 2014;107:110–8.
12. Renukaradhya GJ, et al. Type I NKT cells protect (and type II NKT cells
suppress) the host’s innate antitumor immune response to a B-cell
lymphoma. Blood. 2008;111(12):5637–45.
13. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a
unique subset of major histocompatibility complex class I-specific CD4+
and CD4−8- T cells in mice and humans. J Exp Med. 1994;180(3):1097–106.
14. Ohteki T, MacDonald HR. Stringent V beta requirement for the development
of NK1.1+ T cell receptor-alpha/beta + cells in mouse liver. J Exp Med.
1996;183(3):1277–82.
15. Arase H, et al. An NK1.1+ CD4+8- single-positive thymocyte subpopulation
that expresses a highly skewed T-cell antigen receptor V beta family. Proc
Natl Acad Sci U S A. 1992;89(14):6506–10.
16. Ohteki T, MacDonald HR. Major histocompatibility complex class I related
molecules control the development of CD4+8- and CD4−8- subsets of
natural killer 1.1+ T cell receptor-alpha/beta + cells in the liver of mice. J Exp
Med. 1994;180(2):699–704.
17. MacDonald HR. NK1.1+ T cell receptor-alpha/beta + cells: new clues to their
origin, specificity, and function. J Exp Med. 1995;182(3):633–8.
18. Bendelac A, et al. Mouse CD1-specific NK1 T cells: development, specificity,
and function. Annu Rev Immunol. 1997;15:535–62.
19. Dellabona P, et al. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor
is expressed in all individuals by clonally expanded CD4−8- T cells. J Exp Med.
1994;180(3):1171–6.
20. Porcelli S, et al. Analysis of T cell antigen receptor (TCR) expression
by human peripheral blood CD4−8- alpha/beta T cells demonstrates
preferential use of several V beta genes and an invariant TCR alpha
chain. J Exp Med. 1993;178(1):1–16.
21. Liao CM, Zimmer MI, Wang CR. The functions of type I and type II natural
killer T cells in inflammatory bowel diseases. Inflamm Bowel Dis.
2013;19(6):1330–8.
22. Brossay L, et al. CD1d-mediated recognition of an alpha-galactosylceramide
by natural killer T cells is highly conserved through mammalian evolution.
J Exp Med. 1998;188(8):1521–8.
23. Kawano T, et al. CD1d-restricted and TCR-mediated activation of valpha14
NKT cells by glycosylceramides. Science. 1997;278(5343):1626–9.
24. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic
glycolipid antigens by human natural killer T cells. J Exp Med. 1998;188(8):1529–34.
25. Brossay L, et al. Mouse CD1 is mainly expressed on hemopoietic-derived
cells. J Immunol. 1997;159(3):1216–24.
26. Koch M, et al. The crystal structure of human CD1d with and without alpha-
galactosylceramide. Nat Immunol. 2005;6(8):819–26.
27. Zeng Z, et al. Crystal structure of mouse CD1: An MHC-like fold with a large
hydrophobic binding groove. Science. 1997;277(5324):339–45.
28. Zajonc DM, et al. Structural basis for CD1d presentation of a sulfatide
derived from myelin and its implications for autoimmunity. J Exp Med.
2005;202(11):1517–26.
29. Zajonc DM, et al. Structure and function of a potent agonist for the semi-
invariant natural killer T cell receptor. Nat Immunol. 2005;6(8):810–8.
Hung et al. Journal of Biomedical Science  (2017) 24:22 Page 8 of 10
30. Giabbai B, et al. Crystal structure of mouse CD1d bound to the self ligand
phosphatidylcholine: a molecular basis for NKT cell activation. J Immunol.
2005;175(2):977–84.
31. Zajonc DM, et al. Structural characterization of mycobacterial phosphatidylinositol
mannoside binding to mouse CD1d. J Immunol. 2006;177(7):4577–83.
32. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes.
Nat Rev Immunol. 2005;5(5):387–99.
33. Matsuda JL, et al. Tracking the response of natural killer T cells to a
glycolipid antigen using CD1d tetramers. J Exp Med. 2000;192(5):741–54.
34. Hong S, et al. Lipid antigen presentation in the immune system: lessons
learned from CD1d knockout mice. Immunol Rev. 1999;169:31–44.
35. Burdin N, et al. Selective ability of mouse CD1 to present glycolipids: alpha-
galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
J Immunol. 1998;161(7):3271–81.
36. Stetson DB, et al. Constitutive cytokine mRNAs mark natural killer (NK) and
NK T cells poised for rapid effector function. J Exp Med. 2003;198(7):1069–76.
37. Carnaud C, et al. Cutting edge: Cross-talk between cells of the innate immune
system: NKT cells rapidly activate NK cells. J Immunol. 1999;163(9):4647–50.
38. Fujii S, et al. Activation of natural killer T cells by alpha-galactosylceramide
rapidly induces the full maturation of dendritic cells in vivo and thereby
acts as an adjuvant for combined CD4 and CD8 T cell immunity to a
coadministered protein. J Exp Med. 2003;198(2):267–79.
39. Denkers EY, et al. A role for CD4+ NK1.1+ T lymphocytes as major
histocompatibility complex class II independent helper cells in the
generation of CD8+ effector function against intracellular infection.
J Exp Med. 1996;184(1):131–9.
40. Apostolou I, et al. Murine natural killer T(NKT) cells [correction of natural
killer cells] contribute to the granulomatous reaction caused by
mycobacterial cell walls. Proc Natl Acad Sci U S A. 1999;96(9):5141–6.
41. Kakimi K, et al. Natural killer T cell activation inhibits hepatitis B virus
replication in vivo. J Exp Med. 2000;192(7):921–30.
42. Rissoan MC, et al. Reciprocal control of T helper cell and dendritic cell
differentiation. Science. 1999;283(5405):1183–6.
43. Arrenberg P, et al. Oligoclonality and innate-like features in the TCR
repertoire of type II NKT cells reactive to a beta-linked self-glycolipid. Proc
Natl Acad Sci U S A. 2010;107(24):10984–9.
44. Girardi E, et al. Type II natural killer T cells use features of both innate-like
and conventional T cells to recognize sulfatide self antigens. Nat Immunol.
2012;13(9):851–6.
45. Halder RC, et al. Type II NKT cell-mediated anergy induction in type I NKT
cells prevents inflammatory liver disease. J Clin Invest. 2007;117(8):2302–12.
46. Oh SJ, et al. Role of type II NKT cells in the suppression of graft-versus-host
disease. Crit Rev Immunol. 2008;28(3):249–67.
47. Zhang G, et al. Sulfatide-activated type II NKT cells prevent allergic airway
inflammation by inhibiting type I NKT cell function in a mouse model of
asthma. Am J Physiol Lung Cell Mol Physiol. 2011;301(6):L975–84.
48. Ambrosino E, et al. Cross-regulation between type I and type II NKT cells in
regulating tumor immunity: a new immunoregulatory axis. J Immunol.
2007;179(8):5126–36.
49. Chang DH, et al. Inflammation-associated lysophospholipids as ligands for
CD1d-restricted T cells in human cancer. Blood. 2008;112(4):1308–16.
50. Hix LM, et al. CD1d-expressing breast cancer cells modulate NKT cell-
mediated antitumor immunity in a murine model of breast cancer
metastasis. PLoS One. 2011;6(6):e20702.
51. Izhak L, et al. Delicate balance among three types of T cells in concurrent
regulation of tumor immunity. Cancer Res. 2013;73(5):1514–23.
52. Kobayashi E, et al. KRN7000, a novel immunomodulator, and its antitumor
activities. Oncol Res. 1995;7(10–11):529–34.
53. Natori T, Koezuka Y, Higa T. Agelasphins, novel α-galactosylceramides from the
marine sponge Agelas mauritianus. Tetrahedron Lett. 1993;34(35):5591–2.
54. Morita M, et al. Structure-activity relationship of alpha-galactosylceramides
against B16-bearing mice. J Med Chem. 1995;38(12):2176–87.
55. Mizuno M, et al. Synthetic glycolipid OCH prevents insulitis and diabetes in
NOD mice. J Autoimmun. 2004;23(4):293–300.
56. Savage PB, Teyton L, Bendelac A. Glycolipids for natural killer T cells. Chem
Soc Rev. 2006;35(9):771–9.
57. Wu D, Fujio M, Wong CH. Glycolipids as immunostimulating agents. Bioorg
Med Chem. 2008;16(3):1073–83.
58. McCarthy C, et al. The length of lipids bound to human CD1d molecules
modulates the affinity of NKT cell TCR and the threshold of NKT cell
activation. J Exp Med. 2007;204(5):1131–44.
59. Oki S, et al. The clinical implication and molecular mechanism of preferential
IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest.
2004;113(11):1631–40.
60. Wu TN, et al. Avidity of CD1d-ligand-receptor ternary complex contributes
to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci U
S A. 2011;108(42):17275–80.
61. Tashiro T, et al. RCAI-17, 22, 24–26, 29, 31, 34–36, 38–40, and 88, the analogs
of KRN7000 with a sulfonamide linkage: their synthesis and bioactivity for
mouse natural killer T cells to produce Th2-biased cytokines. Bioorg Med
Chem. 2008;16(19):8896–906.
62. Padte NN, et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses
induced by an adenovirus-vectored malaria vaccine in non-human primates.
PLoS One. 2013;8(10):e78407.
63. Wu TA, et al. Phenyl Glycolipids with Different Glycosyl Groups Exhibit
Marked Differences in Murine and Human iNKT Cell Activation. ACS Chem
Biol. 2016. in press.
64. Huang JR, et al. alpha-Galactosylceramide but not phenyl-glycolipids induced
NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell
accumulation via upregulation of egr2/3. J Immunol. 2014;192(4):1972–81.
65. Raju R, et al. Synthesis and evaluation of 3″- and 4″-deoxy and -fluoro
analogs of the immunostimulatory glycolipid, KRN7000. Bioorg Med Chem
Lett. 2009;19(15):4122–5.
66. Prigozy TI, et al. Glycolipid antigen processing for presentation by CD1d
molecules. Science. 2001;291(5504):664–7.
67. Zhou XT, et al. Synthesis and NKT cell stimulating properties of fluorophore-
and biotin-appended 6″-amino-6″-deoxy-galactosylceramides. Org Lett.
2002;4(8):1267–70.
68. Ebensen T, et al. A pegylated derivative of alpha-galactosylceramide exhibits
improved biological properties. J Immunol. 2007;179(4):2065–73.
69. Aspeslagh S, et al. Galactose-modified iNKT cell agonists stabilized by an induced
fit of CD1d prevent tumour metastasis. EMBO J. 2011;30(11):2294–305.
70. Pauwels N, et al. Divergent synthetic approach to 6″-modified alpha-GalCer
analogues. Org Biomol Chem. 2011;9(24):8413–21.
71. Hsieh MH, et al. Synthesis and evaluation of acyl-chain- and galactose-6″-
modified analogues of alpha-GalCer for NKT cell activation. Chembiochem.
2012;13(11):1689–97.
72. Hung J-T, et al. Design and synthesis of galactose-6-OH-modified [small
alpha]-galactosyl ceramide analogues with Th2-biased immune responses.
RSC Adv. 2014;4(88):47341–56.
73. Aspeslagh S, et al. Enhanced TCR footprint by a novel glycolipid increases
NKT-dependent tumor protection. J Immunol. 2013;191(6):2916–25.
74. Park JJ, et al. Synthesis of all stereoisomers of KRN7000, the CD1d-binding
NKT cell ligand. Bioorg Med Chem Lett. 2008;18(14):3906–9.
75. Fuhshuku K, et al. RCAI-8, 9, 18, 19, and 49–52, conformationally restricted
analogues of KRN7000 with an azetidine or a pyrrolidine ring: Their
synthesis and bioactivity for mouse natural killer T cells to produce
cytokines. Bioorg Med Chem. 2008;16(2):950–64.
76. Shiozaki M, et al. Synthesis and biological activity of ester and ether
analogues of alpha-galactosylceramide (KRN7000). Carbohydr Res.
2010;345(12):1663–84.
77. Birkholz AM, et al. A Novel Glycolipid Antigen for NKT Cells That Preferentially
Induces IFN-gamma Production. J Immunol. 2015;195(3):924–33.
78. Li X, et al. Identification of C-glycoside analogues that display a potent
biological activity against murine and human invariant natural killer T cells.
Immunology. 2009;127(2):216–25.
79. Giaccone G, et al. A phase I study of the natural killer T-cell ligand alpha-
galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res.
2002;8(12):3702–9.
80. Crough T, et al. Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age,
malignancy and conventional anticancer therapies. Br J Cancer. 2004;91(11):1880–6.
81. Toura I, et al. Cutting edge: inhibition of experimental tumor metastasis by
dendritic cells pulsed with alpha-galactosylceramide. J Immunol. 1999;163(5):2387–91.
82. van der Vliet HJ, et al. Potent expansion of human natural killer T cells
using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived
dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol
Methods. 2001;247(1–2):61–72.
83. Fujii S, et al. Prolonged IFN-gamma-producing NKT response induced with
alpha-galactosylceramide-loaded DCs. Nat Immunol. 2002;3(9):867–74.
84. Nieda M, et al. Therapeutic activation of Valpha24 + Vbeta11+ NKT cells in
human subjects results in highly coordinated secondary activation of
acquired and innate immunity. Blood. 2004;103(2):383–9.
Hung et al. Journal of Biomedical Science  (2017) 24:22 Page 9 of 10
85. Chang DH, et al. Sustained expansion of NKT cells and antigen-specific T
cells after injection of alpha-galactosyl-ceramide loaded mature dendritic
cells in cancer patients. J Exp Med. 2005;201(9):1503–17.
86. Uchida T, et al. Phase I study of alpha-galactosylceramide-pulsed antigen
presenting cells administration to the nasal submucosa in unresectable or
recurrent head and neck cancer. Cancer Immunol Immunother.
2008;57(3):337–45.
87. Kunii N, et al. Combination therapy of in vitro-expanded natural killer T cells
and alpha-galactosylceramide-pulsed antigen-presenting cells in patients
with recurrent head and neck carcinoma. Cancer Sci. 2009;100(6):1092–8.
88. Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological
effects of intravenous and intradermal administration of alpha-galactosylceramide
(KRN7000)-pulsed dendritic cells. Clin Cancer Res. 2011;17(15):5140–51.
89. Veldt BJ, et al. Randomized placebo controlled phase I/II trial of alpha-
galactosylceramide for the treatment of chronic hepatitis C. J Hepatol.
2007;47(3):356–65.
90. Woltman AM, et al. Alpha-galactosylceramide in chronic hepatitis B
infection: results from a randomized placebo-controlled Phase I/II trial.
Antivir Ther. 2009;14(6):809–18.
91. Osman Y, et al. Activation of hepatic NKT cells and subsequent liver injury
following administration of alpha-galactosylceramide. Eur J Immunol.
2000;30(7):1919–28.
92. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by
alpha-galactosylceramide. J Clin Invest. 2005;115(9):2328–9.
93. Parekh VV, et al. Glycolipid antigen induces long-term natural killer T cell
anergy in mice. J Clin Invest. 2005;115(9):2572–83.
94. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO
Rep. 2008;9(1):50–5.
95. Dugast AS, et al. Myeloid-derived suppressor cells accumulate in kidney
allograft tolerance and specifically suppress effector T cell expansion. J
Immunol. 2008;180(12):7898–906.
96. Hanson EM, et al. Myeloid-derived suppressor cells down-regulate L-selectin
expression on CD4+ and CD8+ T cells. J Immunol. 2009;183(2):937–44.
97. Moline-Velazquez V, et al. Myeloid-derived suppressor cells limit the
inflammation by promoting T lymphocyte apoptosis in the spinal cord of a
murine model of multiple sclerosis. Brain Pathol. 2011;21(6):678–91.
98. Li H, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy
of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182(1):240–9.
99. Bunt SK, et al. Inflammation induces myeloid-derived suppressor cells that
facilitate tumor progression. J Immunol. 2006;176(1):284–90.
100. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived
suppressor cells and induction of M1 macrophages facilitate the rejection of
established metastatic disease. J Immunol. 2005;174(2):636–45.
101. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived
suppressor cells and tolerance in cancer: mechanisms and therapeutic
perspectives. Immunol Rev. 2008;222:180–91.
102. Ochoa AC, et al. Arginase, prostaglandins, and myeloid-derived suppressor
cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):721s–6s.
103. Ito H, Ando T, Seishima M. Inhibition of iNOS activity enhances the anti-
tumor effects of alpha-galactosylceramide in established murine cancer
model. Oncotarget. 2015;6(39):41863–74.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hung et al. Journal of Biomedical Science  (2017) 24:22 Page 10 of 10
